Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease - Project One: A Phase IIB Clinical Trial of the Safety and Efficacy of a NOX1/4 Inhibitor in IPF

Grant

Date/time Interval

  • August 1, 2018 - July 31, 2023

    • Awarded By

    Total Award Amount

  • 925661.00

    • Direct Costs

  • 667489.00

    • Sponsor Award Id

  • P01HL114470

    • Contributor

  • Gary Cutter   Investigator  
  • Joao De Andrade   Investigator  
  • Steven Duncan   Principal Investigator  
  • Tracy Luckhardt   Investigator